Yale team makes breakthrough that will transform the way we study CNS diseases

A paper from the Yale group that provides exquisite validation of the new SV2A radioligand, that Imanova is currently implementing for the measurement of synaptic density, has been published in Science Translational Medicine. 

This breakthrough will transform the way we study CNS diseases and investigate novel therapies with imaging.

Imanova will soon have this tracer available for both academic and commercial studies.

You can read the full paper here http://stm.sciencemag.org/content/8/348

 

Archive